Lonza's (SGX:O6Z) attributable profit to equity holders for 2025 jumped to 949 million Swiss francs from 636 million francs a year earlier, according to a Wednesday filing with the Singapore Exchange.
Earnings per share of the pharmaceutical firm rose to 13.51 francs from 8.49 francs a year earlier.
Sales jumped 19% year over year to 6.53 billion francs from 5.48 billion francs.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.